Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status

Ítems similars

• EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK(+) NSCLC
  per: Christopoulos, Petros, et al.
  Publicat: (2018)
• Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach
  per: Xiao, Zhiguang, et al.
  Publicat: (2019)
• Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)
  per: Morán, Teresa, et al.
  Publicat: (2013)
• Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
  per: Zhang, Xuchao, et al.
  Publicat: (2010)
• The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer
  per: Jia, Xiangbo, et al.
  Publicat: (2016)